New Frontiers for Neuromuscular Blockade Use and Reversal: Managed Care Considerations in an Evolving Paradigm

A continuing medical education activity provided by NAMCP and AAMCN

New Frontiers for Neuromuscular Blockade Use and Reversal: Addressing Challenges for Improved Clinical and Economic Outcomes is a two-part webinar series focusing on the latest developments and management of neuromuscular blockade use and reversal

This is Part 2 of the series on managed care considerations in neuromuscular blockade use and reversal

This activity is an archive from the webinar held August 12, 2020

This activity is valid from August 15, 2020 to August 15, 2022

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Merck Sharp & Dohme Corp.

Description:
Neuromuscular blocking agents (NMBAs) are used in many surgical procedures and have enabled new surgical advances. The expanded landscape of NMB reversal drugs allows for fast and complete neuromuscular blockade (NMB) reversal and the reduction of postoperative complications from residual block. In the United States, neostigmine/glycopyrrolate and sugammadex are the primary agents for pharmacologic antagonism of NMBAs. While neostigmine and an anticholinergic have been available for decades, sugammadex has only recently become available. This webinar will take a close look at these options and what managed care needs to know about NMB and reversal in a variety of surgeries and clinical settings in which the use of NMB reversal agents played a significant role in the patients' clinical outcome.

Upon completion of this activity, participants will be able to:

  • Explain the physiology, incidence, and complications of residual neuromuscular blockade (NMB)

  • Compare the options for neuromuscular blockade reversal and monitoring with regard to efficacy, safety, and pharmacoeconomics

  • Consider patient and procedural risk factors when managing reversal of neuromuscular blockade

  • Analyze recent clinical data on agents available for neuromuscular blockade reversal

  • Assess managed care considerations of NMB reversal agents and the role that payers can play in this paradigm
     

Faculty: Gary Owens, MD
President
Gary Owens Associates

Disclosure:

Dr. Owens has no relevant financial relationships to disclose.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
Merck Sharp & Dohme Corp.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue